centrally located hepatocellular carcinoma
Conditions
Interventions
experimental group:Surgery was performed after preoperative radiotherapy
control group:Radiotherapy after surgery
Sponsors
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years, gender is not limited, volunteer to participate in the study; 2. Those who were diagnosed with central hepatocellular carcinoma by MDT before treatment, and are operable; 3. BCLC stages are A, B or there are adjacent or surrounding blood vessels; 4. Liver function reserve test can tolerate surgery; 5. ECOG score of 0 or 1; 6. The expected survival time is more than 6 months, with follow-up.
Exclusion criteria
Exclusion criteria: 1. Other neoadjuvant therapy before surgery, such as transcatheter hepatic arterial chemoembolization, radiofrequency ablation, targeted drug therapy, etc.; 2. At the same time or in the past with other tumors (except thyroid cancer and skin cancer) or with distant metastasis before randomization; 3. The patient refuses surgery or radiotherapy; 4. Serious underlying diseases, such as heart disease and cerebrovascular disease, cannot be treated or affect the prognosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Cancer specific survival; | — |
Countries
China
Contacts
Public ContactWu Jianxiong
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Outcome results
None listed